Actively Recruiting
Randomized Study of Intravitreal Remigromig EYE103 in Adults with Neovascular Age-Related Macular Degeneration or Macular Edema After Branch Retinal Vein Occlusion
Led by EyeBiotech Ltd. · Updated on 2026-10-20
160
Participants Needed
55
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of intravitreal remigromig EYE103 in adults with neovascular age-related macular degeneration NVAMD or macular edema following branch retinal vein occlusion BRVO. This randomized, dose-masked Phase 2 study includes four patient groups, comparing low and high doses of remigromig, alone or combined with aflibercept for certain participants. The study aims to assess safety and efficacy of these treatments for these eye conditions. Participants will receive three injections of remigromig into the study eye, spaced four weeks apart. In one group of incomplete responders with NVAMD, aflibercept injections are also given on the first day. Participants are randomized within four cohorts to receive either a low or high dose of remigromig, with some receiving combination therapy. Enrollment and treatment timing are managed by the study sponsor. Throughout the study, participants will return for safety and efficacy assessments at each injection visit and may have additional visits two weeks after injections depending on their group. Assessments include vision tests using the ETDRS chart, eye examinations, and imaging to measure retinal thickness. The main outcome measure is the change in best-corrected visual acuity at 12 weeks. The study concludes with a final visit at week 12, after which safety and effectiveness data will be reviewed.
CONDITIONS
Brief Title
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
Research Team
C
Charles Miller, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here